Insiders Updates Tscan Therapeutics Inc (TCRX) receives a Buy rating from BTIG Research Tscan Therapeutics Inc’s recent filing unveils that its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $1.67
Insiders Updates Tscan Therapeutics Inc (TCRX) rating initates by BTIG Research Tscan Therapeutics Inc’s recent filing unveils that its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $1.67